Biomedical Research

Coronary artery disease (CAD) is leading due to disability and death of the working population, and successful its treatment is largely determined by maintaining adequate coronary blood flow, including through interventions, percutaneous interventions. Acetylsalicylic acid is widely used in patients with coronary artery disease (CAD) to prevent major adverse cardiac events (MACE). Lately, attention is increasingly being paid to the variability of the response to antiplatelet therapy. High platelet reactivity increases the risk of ischemic events. The causes of resistance to antiplatelet agents are heterogeneous and multicomponent: clinical, cellular and genetic. This review article describes features and characteristics of the using acetylsalicylic acid- aspirin in CAD, as well as current problems in the antiplatelet therapy.

Author(s): Alyavi Anis, Khodjanova Shakhnoza, Kadirova Shoira
Abstract | Full-Text | PDF

Share this